News &
Press Review

News & Press Review

Here you can find the latest news about Italfarmaco Nordics and the Corporate press reviews.

  • 2024 - September 6

    World Duchenne Awareness Day 2024

    7 September marks World Duchenne Awareness Day (WDAD), a disease in which we as a company are particularly involved.

  • 2024 - June 28

    Italfarmaco partners with Iktos on Artificial Intelligence to speed drugdiscovery breakthroughs for patients

    Combines AI to increase the potential of novel histone deacetylase (HDAC) inhibitors in the non-oncological field

  • 2023 - September 7

    Duchenne Awareness DAY 2023

    7 September marks World Duchenne Awareness Day (WDAD), a disease in which we as a company are particularly involved.

  • 2022 - September 7

    Duchenne Awareness DAY 2022

    September 7th is World Duchenne Muscular Dystrophy Awareness Day, a disease that sees us, as a company, at the forefront of the search for a drug that can slow down its progression.

  • 2022 - July 26

    Italfarmaco acquires 100% of Lacer, a Spanish pharmaceutical company that is a leader in health care and personal hygiene

    Thanks to this operation, that is subject to the approval of the competition authorities, the Group will reach 1,300 employees in Spain and 3,500 globally, with a consolidated turnover of over 1 billion euros.

  • 2020 - September 7

    World Duchenne Awareness Day 2020 – Duchenne and the Brain

    World Duchenne Awareness Day represents a great action of the global Duchenne Community to raise awareness for children and young adults living with Duchenne and Becker Muscular Dystrophy. This year the special theme that deserves more attention is “Duchenne and the brain”.

Press review

2024 – March 21

Business Wire

Italfarmaco receives FDA approval for givinostat in Duchenne muscular dystrophy (DMD)

Read the article

2024 – March 19

Business Wire

Italfarmaco Publishes in The Lancet Neurology results from Phase 3 EPIDYS Study in Duchenne Muscular Dystrophy (DMD)

Read the article

2023 – September 05

Business Wire

Italfarmaco Group Receives EMA Validation of Marketing Authorization Application for Givinostat in Duchenne Muscular Dystrophy

Read the article

2023 – June 29

Business Wire

Italfarmaco Group Completes FDA Submission of New Drug Application for Givinostat in Duchenne Muscular Dystrophy and Receives Priority Review

Read the article

2022 – June 25

Business Wire

Italfarmaco Group Announces Positive Topline Data from Phase 3 Trial Showing Beneficial Effect of Givinostat in Patients with Duchenne Muscular Dystrophy

Read the article